Zentalis Pharmaceuticals Announced That FDA Has Placed A Partial Clinical Hold On ZN-c3-001, DENALI And TETON Monotherapy Studies Of Azenosertib, This Action Follows Two Recent Deaths Due To Presumed Sepsis In DENALI Study
Portfolio Pulse from Benzinga Newsdesk
Zentalis Pharmaceuticals announced that the FDA has placed a partial clinical hold on ZN-c3-001, DENALI, and TETON monotherapy studies of Azenosertib following two recent deaths due to presumed sepsis in the DENALI study.
June 18, 2024 | 11:16 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The FDA has placed a partial clinical hold on Zentalis Pharmaceuticals' Azenosertib studies following two deaths in the DENALI study. This regulatory action could negatively impact Zentalis' stock price in the short term.
The FDA's partial clinical hold on Zentalis' Azenosertib studies is a significant regulatory setback, especially following the deaths in the DENALI study. This could lead to negative investor sentiment and a potential drop in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100